Diabetes Care 34 , 14631468 (2011)
Cropley V, Croft R, Silber B, Neale C, Scholey A, Stough C, Schmitt J
CagriSema Phase 2 Proof-of-Concept (NCT04982575) Study Title: "Efficacy and Safety of Cagrilintide 2.4 mg in Combination With Semaglutide 2.4 mg for Weight Management" Status: Completed Phase: Phase 2 Enrollment: 92 participants Study Period: 2021-2022 Design: Randomized, double-blind, active-controlled Duration: 32 weeks Arms: CagriSema vs
Clinicians should maintain realistic expectations about GLP-1 brain effects, emphasizing established benefits for glycemic control and weight management while acknowledging that applications for cognitive enhancement or neuroprotection remain unproven
The GHRPs are not related structurally or functionally to GHRH
Semaglutide, the drug in Ozempic and Wegovy, is a GLP-1R agonist only